Positive allosteric modulators of mGluR2

Patent metadata

Field	Value
Publication number	US-9108937-B2
Application number	US-201113581819-A
Country	US
Kind code	B2
Filing date	Feb 28, 2011
Priority date	Mar 4, 2010
Publication date	Aug 18, 2015
Grant date	Aug 18, 2015

Abstract

The present invention is directed to 5-substituted 1,3-dihydro-2,1,3-benzothiadiazole 2,2-dioxide and 1,3-dihydro[1,2,5]thiadiazolo[3,4-b]pyridine 2,2,-dioxide derivatives which are potentiators of metabotropic glutamate receptors, particularly the mGluR2 receptor, and which are useful in the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which metabotropic glutamate receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which metabotropic glutamate receptors are involved.

First claim

What is claimed is:

1. A compound according to Formula I

wherein:
X is selected from the group consisting of C and N;
Y is C 1-6 alkyl;
R 1 is selected from the group consisting of:
(1) C 2-8 alkyl,
(2) C 2-8 alkenyl,
(3) C 2-8 alkynyl,
(4) C 3-6 cycloalkyl-(CH 2 ) p —, wherein p is 1, 2, 3 or 4, and
(5) benzyl,

wherein groups (1) to (5) above are opti…

Assignees

• Layton Mark E
• Kelly Michael J
• Hartingh Timothy J
• Merck Sharp & Dohme

Inventors

• Layton Mark E
• Kelly Michael J
• Hartingh Timothy J

Classifications

• A61P43/00

  Human Necessities · mapped topic

• C07D498/04

  Chemistry & Metallurgy · mapped topic

• C07D513/04

  Chemistry & Metallurgy · mapped topic

• C07D417/12

  Chemistry & Metallurgy · mapped topic

• C07D285/14 Primary

  Chemistry & Metallurgy · mapped topic